- US12611404utility2026Aza-aryl 1h-pyrazol-1-yl Benzene Sulfonamides0 cites
- US12611409utility2026Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1/PD-L1 Inhibitor0 cites
- US12533354utility2026Triaryl Compounds for Treatment of PD-L1 Diseases0 cites
- US12497383utility2025Heteroaryl-biphenyl Amides for the Treatment of PD-L1 Diseases0 cites
- US12350263utility2025Dosing and Effect of C5a Antagonist with Anca-associated Vasculitis0 cites
- US12268675utility2025Diaryl Substituted 6,5-fused Ring Compounds as C5ar Inhibitors0 cites
- US12194032utility2025Method of Treating Focal Segmental Glomerulosclerosis0 cites
- US12139475utility20242-oxindole Compounds0 cites
- US12054484utility2024Substituted Tetrahydropyrans as CCR2 Modulators0 cites
- US12012403utility2024Aryl Sulfonyl Compounds as CCR6 Inhibitors0 cites
- US11986466utility2024Methods of Treating Solid Tumors with CCR2 Antagonists0 cites
- US11951214utility2024Capsule Formulations0 cites
- US11945805utility2024Inhibitors of CXCR20 cites
- US11890276utility2024Methods of Treating Pancreatic Cancer0 cites
- US11884654utility2024Substituted Anilines as CCR(4) Antagonists0 cites
- US11872217utility2024Indanes as PD-L1 Inhibitors0 cites
- US11866429utility2024Heteroaryl-biphenyl Amines for the Treatment of PD-L1 Diseases0 cites
- US11844790utility2023Methods of Treating Hidradenitis Suppurativa0 cites
Page 1 of 2Next →